Mr. Aras Azadian reports

AVICANNA TO REPORT Q3 2026 RESULTS AND HOST CALL ON NOV. 12

Avicanna Inc. has set Nov. 12, 2026, as the date for releasing third quarter 2026 financial results, and management will host a live webcast at 8:30 a.m. ET that morning to present the results and provide a corporate update.

Aras Azadian, founder and chief executive officer, and Nick Hilborn, CPA, CA, chief financial officer, will present the quarterly results and discuss the company's strategic outlook, including the recent launch of Quix rapid-onset portfolio, its MyMedi integrated health care program and other priorities heading into 2027. Shareholders, analysts and other interested parties are invited to register.

Webcast details

Date:  Thursday, Nov. 12, 2026

Time:  8:30 a.m. ET

Webcast and registration:  at the Zoom website

About Avicanna Inc.

Avicanna is an international biopharmaceutical company specializing in the commercialization of proprietary and evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments. Avicanna has established scientific and medical affairs platforms that support its four commercial-stage business pillars and have resulted in the commercialization of more than 50 finished products.

• Medical cannabis formulary (RHO Phyto): The formulary offers a diverse range of proprietary products, including oral, sublingual, topical and transdermal deliveries with varying ratios of cannabinoids, supported by continuing patient and medical community education. The portfolio has recently expanded with the launch of Quix rapid onset, a proprietary nano-emulsion technology-based subbrand featuring a range of fast-onset products, including capsules and soft chews, designed to provide rapid onset of action and enhanced bioavailability. RHO Phyto is an established brand in Canada, currently available nationwide across several channels and expanding into new international markets.
• Medical cannabis care platform (MyMedi): MyMedi is a medical cannabis care platform formed with the aim of better serving medical cannabis patients' needs and enhancing the patient journey. MyMedi is operated by Northern Green Canada Inc., and features a diverse portfolio of products and bilingual pharmacist-led patient support programs. MyMedi also provides specialty services to distinct patient groups such as veterans and collaborates with public and private payers for adjudication and reimbursement. MyMedi provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens.
• Pharmaceutical pipeline: Leveraging Avicanna's scientific platform, vertical integration and real-world evidence, Avicanna has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. These cannabinoid-based candidates aim to address unmet needs in the areas of dermatology, chronic pain and various neurological disorders.
• Active pharmaceutical ingredients (Aureus Santa Marta): The company's majority-owned subsidiary, Santa Marta Golden Hemp SAS, is a commercial-stage business dedicated to providing various forms of high-quality cannabidiol, tetrahydrocannabinol and cannabigerol to the company's international partners for use in the development and production of food, cosmetics, medical and pharmaceutical products. SMGH also forms part of the company's supply chain, and is a source of reliable input products for its consumer retail, medical cannabis and pharmaceutical products globally.

We seek Safe Harbor.